Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled adjuvant recPRAME + AS15 in resected PRAME-positive NSCLC
2012-002790-55Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing recPRAME + AS15 with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Mar 2013; status: completed.
02
Drugs
recPRAME + AS15
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-002790-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002790-55.